Abstract #3678
Quantitative Susceptibility Mapping as an Alternative to CT for Localizing Gold Intraprostatic Fiducial Markers
Ashley Wilton Stewart1,2, Jonathan Goodwin3,4, Simon Daniel Robinson2,5,6, Kieran O’Brien1,2,7, Jin Jin1,2,7, Markus Barth1,2,8, and Steffen Bollmann1,2,8
1ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, St Lucia, Australia, 2Centre for Advanced Imaging, The University of Queensland, St Lucia, Australia, 3Department of Radiation Oncology, Calvary Mater Hospital, Newcastle, Australia, 4School of Information and Physical Sciences, University of Newcastle, Newcastle, Australia, 5High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, 6Department of Neurology, Medical University of Graz, Graz, Austria, 7Siemens Healthcare Pty Ltd, Brisbane, Australia, 8School of Information Technology and Electrical Engineering, The University of Queensland, St Lucia, Australia
Synopsis
Gold fiducial markers (FMs) for prostate radiotherapy are commonly localized using Computed Tomography (CT), though interest in MR-only workflows is growing. One current limitation with magnitude-based MR-only workflows is the ability to distinguish FMs from blood products and calcifications because all appear as signal voids. Quantitative Susceptibility Mapping (QSM) separates sources based on their susceptibility, and may be a potential solution. We apply the QSMxT pipeline to gradient-echo images of a prostate cancer patient with FMs and a calcification. We found that QSM provided a contrast that could differentiate the FMs from calcifications to a degree comparable to CT.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
